One pre-loaded 3 ml multi-dose pen, eight pen needles, a printed guide and a verification sticker. The certificate of analysis for your batch is one QR scan away. Everything ships in an insulated cold-chain box with a cooling element and a temperature indicator.
An independent laboratory tests every batch for identity, purity and sterility. Scan the QR code on your pen, or open the certificate index, to download the certificate of analysis for your exact batch.
↓ Download COA (PDF)Order before 12:00 on a business day and your pen leaves the same day in cold-chain packaging. Delivery across Europe takes 3–5 business days, tracked door to door. Unopened pens in their sealed packaging can be returned within 30 days of delivery; opened or used pens cannot. If your pen arrives broken or does not work, we replace it free of charge once you send us photos or a short video of the fault.
For research reference only. These tables separate established clinical dosing from research-use guidance and are not medical instructions or a recommendation for human use. Body Pharm research pens are not approved medicines. Always consult a qualified clinician.
There is no authorised human dosage, and the FDA reports it has not identified human exposure data adequate to establish safety.
| Research tier | Reported dose | Frequency | Cycle |
|---|---|---|---|
| Introductory | 5 mg | Once weekly | ~4 weeks |
| Common practitioner protocol | 5 mg | Twice weekly | 8–12 weeks |
| Higher practitioner protocol | 5 mg | 2–3× weekly | ~8 weeks |
| Pulse protocol | 5 mg | Every five days | Four administrations |
No human trial supports a defined schedule; reported protocols vary widely.
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome rather than the nucleus. In cells and in mice it acts as a metabolic signal, switching on AMPK, the enzyme cells use to sense low energy.
That unusual origin is why we file it under mitochondrial peptides, and why it draws more attention than its evidence base has yet earned. The full published record is at what is MOTS-c?.
The findings come from cell culture and from mice: MOTS-c treatment protected against age- and diet-related insulin resistance and against diet-induced obesity. In people the data are observational. Exercise raises the body's own MOTS-c, and plasma levels fall with age.
No randomised trial of injected MOTS-c in humans has been published, so no outcome is established. MOTS-c holds no marketing authorisation anywhere.
No human dose-ranging trial has been published for MOTS-c, so there is no established dose. Figures circulating online are not traceable to a controlled study.
The pen dials in fixed increments. Whether to use it, and at what amount, is a decision for a qualified clinician who knows your history.
Keep the pen in the fridge between uses. Attach a fresh needle, dial the dose your clinician has set, press the button until the counter returns to zero, and hold for six seconds before withdrawing the needle.
Your printed guide covers the pen step by step. The schedule itself is the one you have agreed with your clinician, not one we set.
Educational content only — not medical advice. Consult your clinician before starting any protocol.
Amazing product. It arrived quickly. Absolutely love it.
Reviews are written by customers after delivery and checked by our team before publication. They describe personal experience, not clinical evidence.
Our MOTS-c pen holds 32 mg in 3 ml as a pre-loaded multi-dose pen. MOTS-c is one of the more interesting molecules in this catalogue on mechanistic grounds, because it is encoded in mitochondrial rather than nuclear DNA, and one of the least developed clinically. Both facts belong on the same page. Batch certificates are published on our certificates page.
The foundational work is well cited and entirely preclinical. No human efficacy trial has been published. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21(3):443–454. PMID 25738459; MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. PMC5116416; Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC9854231; The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? PMID 26289118
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA. Almost every peptide of research interest is encoded in nuclear DNA; MOTS-c is not.
That is unusual, and it is the reason the 2015 paper attracted the attention it did. It suggested mitochondria act as a signalling origin rather than only as an energy-producing organelle: a conceptual shift rather than an incremental finding.
It also explains why MOTS-c gets filed alongside NAD+ under headings like “mitochondrial peptides” despite the two being completely different kinds of molecule. NAD+ is a coenzyme, not a peptide. That confusion is addressed at mitochondrial peptides.
The 2015 work identified skeletal muscle as the primary target organ. The described cellular route is inhibition of the folate cycle and the de novo purine biosynthesis tethered to it, producing a large increase in endogenous AICAR, reported as greater than twenty-fold, which in turn activates AMPK signalling.
AMPK is a central metabolic sensor, which is why activating it is the mechanistic hook for essentially every metabolic claim made about this compound.
In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity, the finding behind the weight-loss listing. Later work explored relationships between exercise, dietary intervention, ageing and MOTS-c production, with skeletal muscle as the main target of the circulating peptide and evidence pointing to fat cells as a further one.
Every one of those findings is from cell culture or rodent models. No published human efficacy trial exists. There is no established human dose, no human safety dataset, and no clinical outcome data of any kind.
The gap between “prevented diet-induced obesity in mice” and any statement about a person is the entire distance between preclinical and clinical evidence, and no amount of mechanistic elegance closes it.
Queries about MOTS-c are dominated by PubMed Central, anti-doping bodies and reference sources rather than by merchants. That reflects the compound’s actual position: it is an active research subject with a real literature and no commercial clinical development behind it.
We mention this because it shapes what an honest page can offer. On a compound this early, the useful contribution is an accurate statement of what has been shown and in what species, not a longer version of the same mechanistic summary.
A pre-loaded pen containing 32 mg of MOTS-c in 3 ml, tested per batch by an independent laboratory for identity, purity and sterility, with the certificate for your batch reachable from the QR code on the pen. The parcel holds the pen, eight pen needles, a printed guide and a verification sticker, in insulated cold-chain packaging with a cooling element and a temperature indicator. MOTS-c holds no marketing authorisation anywhere.
What we can evidence is what is in the pen. What we cannot evidence, and will not imply, is an outcome in a human being, because nobody has published one, under this heading or under peptides for longevity. The pen is also sold with NAD+ 1000 as the Metabolic Reset set; no study has tested the two together.
Related: what is MOTS-c?, MOTS-c vs NAD+, peptides for energy, the recovery goal page.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy